Speedway Scene
Markets S&P 500 7,500.58 ▲ 0.00% Nasdaq 26,517.93 ▲ 0.00% Dow Jones 44,200.00 ▲ 0.00% US 10 Yr 4.45 ▲ 0.00% Crude Oil 76.54 ▲ 0.00% Gold 2,350.00 ▲ 0.00% Bitcoin 64,000 ▲ 0.00% FTSE 100 8,400.00 ▲ 0.00% EUR/USD 1.0850 ▲ 0.00% Nikkei 225 39,000.00 ▲ 0.00%
Topic archive

orforglipron

Reporting, analysis and commentary on orforglipron from Speedway Scene, drawn together from across our coverage.

1 article Latest update: 4 Jul 2026 1 section
Related sections Health
Related topics Eli Lilly Foundayo weight loss pill Medicare GLP-1 drugs obesity treatment weight loss health policy
Tag lead
A pharmacist holding a bottle of Eli Lilly Foundayo orforglipron oral weight loss tablets at a pharmacy counter
Health

How the Eli Lilly Foundayo weight loss pill reaches Medicare patients for a $50 copay

Foundayo, Eli Lilly's oral GLP-1 pill approved by the FDA on April 1, 2026, becomes available to eligible Medicare beneficiaries for a flat $50 monthly copay starting July 1 under a federal demonstration program running through 2027.

4 Jul 2026 ·8 min read
Keep reading

More paths through this story

This archive gathers Speedway Scene coverage of orforglipron, bringing together the reporting, analysis and commentary connected to the subject.

Related topics

Eli Lilly Foundayo weight loss pill Medicare GLP-1 drugs obesity treatment weight loss health policy Federal Reserve Donald Trump AI infrastructure semiconductors

Related sections

Health

Latest nearby

Health · 4 Jul 2026 Aetna, Cigna Headline ACA Marketplace Insurers Exit 2026 Health · 4 Jul 2026 Dead Skua Marks First H5N1 Bird Flu Australia Detection Health · 4 Jul 2026 European heatwave 20000 deaths study exposes a toll ten times official counts Health · 4 Jul 2026 Gedatolisib Breast Cancer FDA Verdict Nears for Patients Out of Options